Glaukos (GKOS) said Thursday it launched Epioxa for the treatment of keratoconus, a rare eye disease.
The drug is commercially available through direct ordering and the company's specialty pharmaceutical distribution network, Glaukos said.
Glaukos shares were down 0.9% in Thursday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.